Donor-specific anti-HLA antibodies (DSA) have been reported to be associated with graft failure in mismatched hematopoietic stem cell transplantation; however, their role in the development of graft failure in matched unrelated donor (MUD) transplantation remains unclear. We hypothesize that DSA against a mismatched HLA-DPB1 locus is associated with graft failure in this setting.
INTRODUCTION
Hematopoietic stem cell transplantation is an effective treatment for a broad range of hematologic malignancies. 1 Approximately 70% of patients do not have a matched related donor available for transplantation. 2 For these patients, a matched unrelated donor (MUD) transplant is preferred, due to similar transplant outcomes. 3, 4 HLA typing is generally performed for 4 HLA loci (HLA-A,-B,-C,-DRB1) as mismatches at HLA-DQB1,-DPB1 did not have a major effect on outcomes. 5 Approximately 86% of MUD transplants are mismatched at least one HLA-DPB1 antigen in the host-versus-graft (HvG) direction. 6 Graft failure occurs more frequently in alternative donor transplants, with a incidence that varies between 4% in MUD transplantation, up to 20% in cord blood and T-cell depleted haploidentical stem cell transplantion. [7] [8] [9] Despite advances in HLA matching and supportive care, graft failure remains an important problem due to a high treatment-related mortality associated with this event.
The etiology of graft failure remains elusive in most patients. We have recently identified a high risk of graft rejection in patients with donor-specific anti-HLA antibodies (DSA) undergoing Tcell depleted haploidentical stem cell transplantation. 10 Patients had DSA directed against high expression loci (HEL) including HLA class I (HLA-A,-B) and class II (-DRB1) antigens. 10 It is unclear if anti-HLA antibodies directed against low expression loci (LEL) (HLA-DPB1, -DQB1) associate with graft failure in this setting. Here we hypothesized that anti-HLA antibodies directed against LEL are deleterious to engraftment, and investigated the role of anti-DPB1 DSA in a cohort of patients who underwent a MUD stem cell transplant at a single institution.
METHODS
For personal use only. on July 14, 2017 . by guest www.bloodjournal.org From Table 1 . Patients received either a myeloablative (41%) or a reduced-intensity/nonmyeloablative conditioning regimen (defined as busulfan < 520 mg/m2, melphalan < 140mg/m2, total-body irradiation < 6Gy). All patients received anti-thymocyte globulin on days -3, -2 and -1. Among the DRB1 mismatched transplants there were no mismatches in DQB1 alleles; 8 of the 9 DRB1 transplants presented allele level mismatches in the subtypes of HLA-DRB1*11 (n=6), DRB1*01 and DRB1*14. One transplant presented an antigen level mismatch in DRB1 in the The difference in the expressed and non-expressed alleles was the most common mismatch in DRB4. In the present study there were 10 cases with a single mismatch in DRB4; one of these cases included the allele level mismatch DRB4*01:03/01:02; the remaining 9 cases included the presence or absence of the null allele DRB4*01:03N; 4 of the mismatches occurred in the HvG vector and 5 of them in the GvH vector.
In total there were 31 transplants that presented a mismatch in DQB1; of these, 30 had the mismatch in both directions and only one presented the mismatch in DQB1 only in the GvH Among the patients with mismatches in DQB1 the anti-HLA antibody tests showed that 19 of them did not have anti-HLA antibodies. Among the 11 patients with DQB1 mismatches and anti-HLA antibodies 9 did not have any anti-HLA class II antibodies. There were 2 patients that presented mismatches in DQB1 whose serum showed anti-DQ reactivity; in both cases there was no reactivity with antigen preparations bearing the donor's DQB1 mismatched allele; neither of the sera showed anti-DQA1 specificity.
The objectives of this study were to determine if there is an association between anti-HLA antibodies, DSA and primary graft failure (N=9), or early death without engraftment beyond the median time to engraftment (N=10) in MUD hematopoietic stem cell transplantation. We also assessed the impact of gender and number of prior pregnancies on the probability of allosensitization. This retrospective study protocol and a waiver of informed consent were approved by the UTMDACC Institutional Review Board (IRB).
Measurement of anti-HLA antibody levels
The presence of DSA was determined by testing the pre-transplant patients' sera prospectively with a panel of fluorescent-beads coated with single HLA antigen preparations (LABScreen® Single-Antigen, One Lambda, Canoga Park, CA).
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The anti-HLA antibody reactivity was detected in a Luminex platform (Luminex™, Austin, TX). 10 The reactivity of HLA antibodies was defined by testing two panels of HLA molecules, which included a set of single-antigen preparations for assignment of specificity, and confirmed by comparison with the reactivity against a panel of HLA class I or class II antigen preparations extracted from lymphocytes from single subjects. Over the course of this study several lots of reagents were used; these were validated prior to use with specimens tested with lots used previously. There were sera from 20
patients that showed anti-DP activity; these sera were tested with more than lot showing concordant results in terms of specificity from lot to lot. The specificity of anti-DP antibodies was examined in the context of DPB1 alleles present in the donor; the patterns of anti-DP reactivity were also interpreted attempting to evaluate possible epitopes recognized in the patient's sera.
The putative epitopes recognized by DSA are listed in Table 2 . There were 20 patients whose sera reacted with HLA-DP molecules, 19 of them recognizes unambiguously epitopes present in the DPB1 subunit and one recognized an epitope present in DPA1 subunits bearing the alleles DPA1*02:01 and DPA1*04:01. The final DSA was assessed by comparing the high-resolution typing of the donor and antigen panels. Antibody levels were interpreted as normalized fluorescence intensity (FI) as defined by the kit's manufacturer against DSA mismatch. FI <500 was considered negative, while positive FI ranging 500-1500, 1500-3000, 3000-7000, and >7000
were considered weak, intermediate, strong and very strong, respectively. HLA-A, -B, -C, -DRB1, -DRB3/4/5, -DQB1 and -DPB1 high-resolution typing was accomplished by PCR amplification combined with nucleotide sequencing. In the present study DPA1 and DQA1 were not typed; possible DSA against alleles of these loci were examined by inferring the alleles likely to be present at these loci from the tight associations with alleles at the contiguous DPB1 and DRB1/DQB1 loci, respectively. 12, 13 No transplants were performed in patients presenting DSA against either HLA-A, B, C or DRB1 antigens. There were no transplants performed across DSA 
Statistical analysis
Descriptive statistics including frequency (percentage) for categorical variables and median (range) for quantitative variables were used to summarize patient characteristics. Fisher's exact test and generalized Fisher's exact tests were used to assess possible associations between anti-HLA antibodies, DSA and graft failure.
14 Univariate and multivariate logistic Bayesian regression models were fit to assess the associations between various risk factors and graft failure. 15 The association between number of pregnancies and anti-HLA antibodies was assessed by fitting a
For personal use only. on July 14, 2017. by guest www.bloodjournal.org From logistic regression model, within females and in all patients. The cumulative incidence of absolute neutrophil count (ANC) recovery (i.e., reach of ANC 500/µL for 3 consecutive days) was calculated, where death without ANC recovery was treated as the competing event. 16 Computations for all statistical analyses were conducted in SAS 9.0 17 and Winbugs version 1.4.
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RESULTS
Association between Anti-HLA Antibodies, Donor Specific Antibodies (DSA) and Graft
Failure
Of 592 patients evaluated, 116 (19.6%) were found to have anti-HLA antibodies which were not reactive with donor loci, while 8 patients (1.4%) had DSA. All DSA were directed against the -DPB1 molecule, specificities of these antibodies are presented in Table 2 . Table 2 also includes possible epitopes recognized by allo-antibodies and the ranges of MFI observed in individual antigen preparations. The reactivity of the patient's sera correlated with specific amino acid replacements on DPB1 alleles present in the donor and in other alleles.
In addition to the above mentioned patients we identified 12 other patients whose sera displayed anti-DP reactivity; all them achieved allogeneic engraftment. The serum of 11 of these patients showed reactivity that exquisitely correlated with epitopes present in the DPB1 alleles; the serum of 1 patient showed reactivity that correlated with the recognition of an epitope present in DPA1 alleles. In the 11 cases with reactivity against DPB1 there was no reactivity against antigen preparations bearing the DPB1 antigens present in the donor and none of the DPB1 alleles present in the donors bore the putative epitopes. The likely anti-DPA1 reactivity was defined in one serum based on the exact correlation with the presence of an epitope shared by DPA1 patients engrafted in the two groups, respectively (p=NS). In terms of time to engraftment, a nonsignificant trend towards a higher engraftment rate was found for an 8/8 vs. 7/8 HLA allele matched donor (p=0.053, log rank test) (Figure 1 ). In the 7/8 group there were no patients with DSA, as all patients with DSA were in the 8/8 group.
Multivariate Bayesian logistic regression models were fit for the probability of engraftment based on mismatches in HEL, LEL, anti-HLA antibodies and DSA (Table 3 a Table 2) .
Risk Factors for the Development of Anti-HLA Antibodies
We have previously observed a striking association between gender of patients who experience graft failure and the development of allosensitization; all patients with DSA were multiparous young females with a median of 3 pregnancies. 10 This study confirms a significant association between female gender, the development of allosensitization, and the presence of DSA; 30.8% of
.1% of males had anti-HLA antibodies (p<0.0001) and 7 out of 8 patients with DSA were females, all except one with at least 2 prior pregnancies. When the presence of anti-HLA antibodies was evaluated in females with no pregnancies as compared with male recipients, no significant association was identified (p=0.24, OR = 2.1, 95% CI 0.62-6.94). However, when allosensitization was compared between females with one prior pregnancy and males, a higher proportion of female patients had anti-HLA antibodies (p=0.008, OR 6.3, 95% CI 1.62-24.95).
Moreover, a stronger association was found between females with 2 or more pregnancies and males (p=0.0003, OR = 9.5, 95%CI 2.83-32.02). These results suggest that pregnancy confers a significant risk for allosensitization, and the risk is further increased with a higher number of pregnancies. Although the majority of allosensitized individuals in this study were females, approximately 12% of patients with anti-HLA antibodies were males (and 1 patient had DSA), suggesting that other factors are associated with the development of anti-HLA antibodies in these patients. The likely cause of allosensitization in these patients is transfusion of blood products, factor not evaluated in this study due to incomplete transfusion history data as many patients were initially treated or receive blood products intermittently at outside institutions.
Expression of HLA-DP Antigens on Normal Progenitor Cell Surface
As compared with our previous experience in T-cell depleted haploidentical stem cell transplantation, the risk of graft failure in the presence of DSA appears less in T-cell replete unrelated donor transplants. 10 We hypothesized that a lower expression of HLA-DP antigens on progenitor cell surface could explain at least in part this difference, and evaluated 8 normal donor bone marrow and peripheral blood samples for the presence of anti-HLA antigens on the CD34+
progenitor cell surface (Figure 2 ). HLA-DP was found to be significantly less expressed on normal CD34+ cells compared with HLA class I antigens (HLA-A,-B,-C) (median 36.1% vs. 
DISCUSSION
Allosensitization remains an important problem in transplantation. Anti-HLA antibodies have been shown to be associated with graft rejection in solid organ transplantation. [19] [20] [21] More recently, an association between anti-HLA antibodies and graft failure has been found in hematopoietic stem cell transplantation. 10, 22, 23 All these groups confirmed a higher risk of graft failure in the presence of DSA in different types of transplants with mismatches.
Here we provide evidence that DSA against low expression HLA antigen DPB1 are also deleterious to engraftment, using a homogenous cohort of matched unrelated donor transplant patients. In multivariate analysis, DSA were the single most important factor associated with graft failure in these patients, while none of the other factors except ABO mismatch were associated with an increased risk of graft failure, including mismatching in HEL or LEL. Interestingly, having an HLA mismatch by itself was not associated with a significantly higher risk of graft failure unless associated with DSA. Moreover, alloimmunization per se did not cause a significant increase risk of graft failure unless antibodies were directed against the donor HLA antigens, suggesting that DSA are the key to the development of graft failure. These results, optimal hematopoietic cell engraftment. 24 The plasmacytoid dendritic cells have been shown to express a high level of HLA-DP antigen. 25 In the 8 cases we studied, although the dendritic cells
were not specifically studied, the monocytes including dendritic cells as identified by CD45/side scatter, showed variable HLA-DP expression.
This study also shows that a cause of allosensitization is the exposure of the fetus' HLA antigens of paternal origin to the maternal immune system during early pregnancy. Moreover, a higher risk of allosensitization occurs with a higher number of pregnancies, strongly suggesting that pregnancy is the main cause of the development of anti-HLA antibodies in these patients. A second role, not evaluated in the present study, is attributed to transfusions of blood products, as males were allosensitized also, albeit to a significantly lower proportion than females. This observation was more difficult to evaluate due to incomplete data on transfusions of blood products prior to referral for hematopoietic transplantation.
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Anti-HLA antibodies were detected in approximately 20% of MUD transplant recipients which make it a common occurrence in stem cell transplantation. Anti-DP antibodies were found in 20 of 592 (3.4%) of the patients. Of these 20 patients, 4 received a transplant with a matched donor in -DPB1. Sixteen patients with anti-DP antibodies were transplanted with a -DPB1 mismatched donor and DSA was found in 8 of 16 patients (50%). Three of these 8 patients had graft failure.
Virtually all anti-DP reactive sera showed reactivity with multiple alleles of -DPB1 (broadly reactive) recognizing public (supertypic) determinants on the -DPB1 molecules. In other words,
given the cross-reactive nature of anti-DP antibodies, when they are present, they are likely to react with many donors.
While the alleles of DQA1 were not typed in this study, we queried for the possible impact of antibodies directed against DQA1. The alleles of DQA1 show tight linkage disequilibrium with alleles of DQB1 and DRB1; 12 in the studies by Lee and co-workers 6 and Hurley and co-workers 26 , more than 99.8 percent of the transplants matching in DRB1-DQB1 loci also match in DQA1. In the present study, more than 93 percent of the transplants matched in those loci; therefore, this group of transplants most likely includes a few or no mismatches in DQA1. The serum of only two patients in the 40 transplants that presented a mismatch in DQB1 or DRB1 and could be mismatched in DQA1 showed anti-DQ reactivity; neither of these sera presented specificity that could be ascribed to the recognition of epitopes present in DQA1 alleles. Furthermore, we analyzed and made predictions of the possible occurrence of mismatching in DQA1 in the pairs mismatched in either DRB1 or DQB1; we identified that only one transplant that presented a mismatch in DRB1 in the HvG direction was likely to present an additional mismatch in DQA1; in the latter case, the serum of the patient did not show any anti-HLA reactivity. 1 6 We estimated that there very few or no cases in which anti-DQA1 antibodies might have resulted in undetected DSA in the present study. In spite of this evaluation, we propose that prospective typing of DQA1 alleles and screening for anti-DQA1 antibodies may be applicable in allogeneic hematopoietic stem cell transplantation, in particular in transplants presenting mismatches in DRB1 and/or DQB1 alleles. 
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In the eight patients with preformed DSA discussed here, we also evaluated the types of T-cell epitope mismatches in the HvG direction in patients with and without engraftment, according to the epitope matching scoring defined by Fleischhauer and collaborators for DP-immunogenic mismatches. 27 In the 5 transplants in which there was donor engraftment, 2 presented nonpermissive TCE mismatches (DPB1*1001 and DPB1*1401) while in the 3 patients without engraftment two of them presented non-permissive TCE mismatches (DPB1*0301 in both of them). The analysis of the TCE mismatches as well as of -DP serologic epitopes defined by our group 28 in previous studies, and additional possible epitopes listed in Table 2 , did not identify any specific epitope present in the non-engraftment group that was absent in the group of transplants with engraftment. Similarly, neither the nature of the cross-reactivity nor the ranges of fluorescent intensity (MFI) identified distinctive characteristics between the patients with and without engraftment. These analyses performed in our dataset did not allow us to favor either of the hypotheses including humoral or cellular mechanisms for graft failure in the allosensitized patient groups against donor antigens.
Preclinical studies on animal models demonstrated that passive transfer of anti-HLA antibodies can reject the transplanted donor hematopoietic stem cells, and that preformed anti-HLA antibodies are sufficient to cause graft failure. 29, 30 Consequently, attempts to remove anti-HLA antibodies directed against the donor cells prior to transplantation make intuitive sense. In the present study, only two of the eight patients with pre-formed DSA could be treated prospectively using rituximab and plasma exchange. 10 Although there was not complete antibody removal by these steps, the fluorescent intensity against the -DP mismatched antigens decreased significantly in both of them from very high levels, 9497 MFI and 7393 MFI, to moderate or low values post treatment, 3733 MFI and 2759 MFI, respectively. One patient showed engraftment while the other one failed to engraft.
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